B
Bryan Burmeister
Researcher at Princess Alexandra Hospital
Publications - 163
Citations - 8693
Bryan Burmeister is an academic researcher from Princess Alexandra Hospital. The author has contributed to research in topics: Radiation therapy & Chemoradiotherapy. The author has an hindex of 39, co-authored 158 publications receiving 7908 citations. Previous affiliations of Bryan Burmeister include Sir Charles Gairdner Hospital & University of Queensland.
Papers
More filters
Journal ArticleDOI
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial
Bryan Burmeister,Michael A. Henderson,Jill Ainslie,Richard Fisher,Juliana Di Iulio,B. Mark Smithers,Angela Hong,Kerwin F. Shannon,Richard A. Scolyer,Scott Carruthers,Brendon J. Coventry,Scott Babington,João Pedreira Duprat,Harald J. Hoekstra,John F. Thompson +14 more
TL;DR: Risk of lymph-node field relapse was significantly reduced in the adjuvant radiotherapy group compared with the observation group, and patients at high risk of relapse after therapeutic lymphadenectomy for metastatic melanoma were better able to control lymph- node field control.
Journal ArticleDOI
Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05)
Daniel E. Roos,Sandra Turner,Peter C. O'Brien,Jennifer G. Smith,Nigel Spry,Bryan Burmeister,Peter Hoskin,David Ball +7 more
TL;DR: 8/1 was not shown to be as effective as 20/5, nor was it statistically significantly worse, although outcomes were generally poorer for 8/1, although the quantitative differences were relatively small.
Journal ArticleDOI
Results of a prospective study of positron emission tomography–directed management of residual nodal abnormalities in node‐positive head and neck cancer after definitive radiotherapy with or without systemic therapy
Sandro V. Porceddu,Sandro V. Porceddu,David Pryor,Elizabeth Burmeister,Bryan Burmeister,Bryan Burmeister,Michael Poulsen,Michael Poulsen,Matthew Foote,Benedict Panizza,Benedict Panizza,Scott Coman,David McFarlane,William B. Coman,William B. Coman +14 more
TL;DR: The purpose of this study was to present the prospectively evaluated positron emission tomography (PET)‐directed policy for managing the neck in node‐positive head and neck squamous cell carcinoma after definitive radiotherapy with or without concurrent systemic therapy.
Journal ArticleDOI
Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial
Michael A. Henderson,Bryan Burmeister,Jill Ainslie,Richard Fisher,Juliana Di Iulio,B. Mark Smithers,Angela Hong,Kerwin F. Shannon,Richard A. Scolyer,Scott Carruthers,Brendon J. Coventry,Scott Babington,João Pedreira Duprat,Harald J. Hoekstra,John F. Thompson +14 more
TL;DR: Adjuvant radiotherapy could be useful for patients for whom lymph-node field control is a major issue, but entry to an adjuvant systemic therapy trial might be a preferable first option.
Clinical practice guidelines for the management of melanoma in Australia and New Zealand
Joanne F. Aitken,Andrew Barbour,Bryan Burmeister,Simon Taylor,Euan Walpole,Bernhard M. Smithers +5 more
TL;DR: In the absence of any substantial evidence as to its effectiveness in reducing mortality population-based screening cannot be recommended and evidence-based guidelines are aimed at encouraging improved management through evidence- based decision-making.